Because the drug has a ~6-day half-life, missing a single weekly injection by a day or two will not collapse your therapeutic drug levels
The FDA approved Foundayo for two primary indications: Chronic weight management: In adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or high cholesterol
Diabetologia 13 , 131135 (1977)
Body Composition Preservation: While older weight-loss methods stripped both fat and muscle, GLP-1 therapycombined with adequate protein and resistance exercise, preferentially preserves lean muscle mass, protecting your metabolic rate and functional capacity
Take the Next StepThe OASIS Advantage Are you tired of pain, fatigue, and insurance denials
That means that even with an obesity diagnosis and a prescription, people will have to pay for the GLP-1 out of pocket